Palvella Therapeutics, Inc. PVLA
163.94 USD -4.77 (-2.83%)
At closeNov 11, 2026, 4:00 PM EST
163.94 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
163.63 Day range 171.72
72.23 52-week range 179.95
- YTD
- +56.63%
- 1 year
- +110.58%
- Market cap
- 2.40B
- EPS (ttm)
- -5.53
- Shares out
- 14.62M
- Forward P/E
- -20.31
- YTD return
- +56.63%
- 1-year return
- +110.58%
- Volume
- 241.51K
- Avg volume
- 235.65K
- Open
- 168.81
- Previous close
- 168.71
- Day's range
- 163.63 – 171.72
- 52-week range
- 72.23 – 179.95
- Analysts
- Strong Buy
- Price target
- 233.80 (+42.6%)
- Earnings date
- Mar 30, 2027
5D +11.50 (+7.42%)
Key statistics
- Enterprise value
- 2.26B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 12.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -27.99M
- Total cash
- 236.68M
- Total debt
- 25.41M
- Return on equity
- -63.39%
- Short % of float
- 20.11%
- 50-day average
- 143.34
- 200-day average
- 129.32
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 233.80 +42.6% upside
Now 163.94
- Target (low)
- 207.00
- Target (mean)
- 233.80
- Target (high)
- 267.00
Ratings (0m) 16 16 buy · 0 hold · 0 sell
- Strong buy0
- Buy16
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 30, 2027
Expected Mar 30, 2027. Consensus EPS estimate -1.79.
Financials — quick view
PVLA Revenue — quarterly 0
PVLA Net income — quarterly -24.64M
PVLA EPS — quarterly -1.70
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 30, 2027 | Dec 30, 2026 | -1.85 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -1.78 | -1.70 | +0.08 | +4.49% |
| Aug 4, 2026 | Jun 30, 2026 | -1.17 | -1.52 | -0.35 | -29.91% |
| May 7, 2026 | Mar 31, 2026 | -0.90 | -1.20 | -0.30 | -33.33% |
| Mar 31, 2026 | Dec 31, 2025 | -0.91117 | -1.08 | -0.17 | -18.53% |
| Nov 11, 2025 | Sep 30, 2025 | -0.85 | -1.03 | -0.18 | -21.18% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 6, 2026 | Oppenheimer | main | Outperform | Outperform |
| Oct 28, 2026 | Chardan Capital | main | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 12, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 21, 2026 | Chardan Capital | main | Buy | Buy |
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- palvellatx.com
News
2,882 Palvella Therapeutics, Inc. $PVLA Shares Bought by Calamos Advisors LLC 
Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $243 
Palvella Therapeutics, Inc. (PVLA) Q3 2026 Earnings Call Transcript 
Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232 
What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call 
Palvella Therapeutics Q3 2026 Earnings Call Transcript - Palvella Therapeutics Q3 EPS $(1.70) Beats $(1.82) Estimate
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating 
Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday
Your note
Sign in to keep a note on PVLA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOIN KATHLEEN | Chief Operating Officer | Conversion of Exercise of derivative security | Aug 18, 2026 | 0 |
| HERON ELAINE J | Director | Purchase | Feb 26, 2026 | 53,691 |
| JENKINS GEORGE M | Director | Sale | Oct 13, 2026 | 146,132 |
| KIRITSY CHRISTOPHER P | Director | Conversion of Exercise of derivative security | Sep 1, 2026 | 250 |
| KORENBERG MATTHEW E | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 11, 2026 | 1,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Montanova Capital LLC | 7.77% | 1,135,406 | 186.14M | Jun 29, 2026 |
| Jennison Associates LLC | 6.57% | 960,619 | 157.48M | Jun 29, 2026 |
| Blackrock Inc. | 6.28% | 918,357 | 150.56M | Jun 29, 2026 |
| Frazier Life Sciences Management, L.P. | 6.04% | 882,400 | 144.66M | Jun 29, 2026 |
| First Light Asset Management, LLC | 5.28% | 771,901 | 126.55M | Jun 29, 2026 |
| BVF Inc. | 4.60% | 672,789 | 110.30M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.66% | 388,390 | 63.67M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.48% | 362,314 | 59.40M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.11% | 308,699 | 50.61M | Sep 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 1.89% | 276,556 | 45.34M | Jul 30, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.58% | 231,484 | 37.95M | Jun 29, 2026 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 1.45% | 212,225 | 34.79M | Sep 29, 2026 |